Table 4.

Results of the deterministic sensitivity analysis of posaconazole versus SAT in the prevention of IFI among high-risk neutropenic patients

Parameter	Sensitivity analysis value	ICER (cost per IFI avoided)	ICER (cost per LYS)
Probability of IFI; Posaconazole	0.025	Dominant*	Dominant*
	0.075	Dominant*	Dominant*
Probability of IFI; SAT	0.075	Dominant*	Dominant*
	0.15	Dominant*	Dominant*
Probability of an IFI-related death; Posaconazole	0.2678	Dominant*	Dominant*
	0.4464	Dominant*	Dominant*
Probability of an IFI-related death; SAT	0.3636	Dominant*	Dominant*
	0.6060	Dominant*	Dominant*
Probability of death from other	0.1185	Dominant*	Dominant*
causes; non IFI-related	0.1975	Dominant*	Dominant*
Relative survival; AML	0.16	Dominant*	Dominant*
	0.26	Dominant*	Dominant*
Relative survival; MDS	0.06	Dominant*	Dominant*
	0.10	Dominant*	Dominant*
Total treatment cost per day; Posaconazole	77.77	Dominant*	Dominant*
	129.61	Dominant*	Dominant*
Total treatment cost per day; Fluconazole	12.70	Dominant*	Dominant*
	21.16	Dominant*	Dominant*
Total treatment cost† per day; Itraconazole	16.39	Dominant*	Dominant*
	27.31	Dominant*	Dominant*
Discount rate for costs and benefits	0%	Dominant*	Dominant*
	5%	Dominant*	Dominant*

*Dominant strategy: posaconazole has lower cost and higher efficacy (measured as IFI avoided and LYS) compared to SAT (standard azole treatment: fluconazole/itraconazole)

^†In euros at November 2009 prices